Watanabe, M.; Yakushijin, K.; Funakoshi, Y.; Ohji, G.; Hojo, W.; Sakai, H.; Saeki, M.; Hirakawa, Y.; Matsumoto, S.; Sakai, R.;
et al. The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation. Vaccines 2022, 10, 158.
https://doi.org/10.3390/vaccines10020158
AMA Style
Watanabe M, Yakushijin K, Funakoshi Y, Ohji G, Hojo W, Sakai H, Saeki M, Hirakawa Y, Matsumoto S, Sakai R,
et al. The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation. Vaccines. 2022; 10(2):158.
https://doi.org/10.3390/vaccines10020158
Chicago/Turabian Style
Watanabe, Marika, Kimikazu Yakushijin, Yohei Funakoshi, Goh Ohji, Wataru Hojo, Hironori Sakai, Miki Saeki, Yuri Hirakawa, Sakuya Matsumoto, Rina Sakai,
and et al. 2022. "The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation" Vaccines 10, no. 2: 158.
https://doi.org/10.3390/vaccines10020158
APA Style
Watanabe, M., Yakushijin, K., Funakoshi, Y., Ohji, G., Hojo, W., Sakai, H., Saeki, M., Hirakawa, Y., Matsumoto, S., Sakai, R., Nagao, S., Kitao, A., Miyata, Y., Koyama, T., Saito, Y., Kawamoto, S., Ito, M., Murayama, T., Matsuoka, H.,
& Minami, H.
(2022). The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation. Vaccines, 10(2), 158.
https://doi.org/10.3390/vaccines10020158
